NeuroAge is not currently hiring. If you receive a message offering you a job from someone supposedly at NeuroAge, that's not us, it's a scam. Please don't interact with them or give them any sensitive information.
NeuroAge Therapeutics
生物技术研究
San Francisco，CA 1,321 位关注者
A longevity pharmatech that creates drugs to rejuvenate biological brain aging and treat neurodegenerative disorders.
关于我们
Longevity biotech company that creates new drugs to rejuvenate biological brain aging and treat neurodegenerative disorders using our ML aging clock platform.
- 网站
-
https://neuroagetx.com/
NeuroAge Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- San Francisco，CA
- 类型
- 私人持股
- 创立
- 2022
地点
-
主要
获取路线
US，CA，San Francisco，94121
NeuroAge Therapeutics员工
-
Salah Mahmoudi
CEO & Co-founder at ReneuBio | Aging & Longevity | Drug Development | Innovator
-
Priyanka Joshi
Biochemist | Co-founder & CSO, NeuroAge Therapeutics | Forbes 30u30 | Berkeley SkyDeck B17
-
Persiana Cota, MA, NBC-HWC
VP of Strategic Partnerships | Health & Wellness Coach
-
Francesco Neri
Scientist @ NeuroAge Therapeutics. Developing therapies to reverse brain aging and treat age-related brain diseases
动态
-
Read here about our new publication in Neuron on innovative drug development for Alzheimer's disease using our new algorithm to predict useful drugs followed by validation in our in Alzheimer's-in-a-Dish? models: https://lnkd.in/eCz8Dm8c
-
Apply to present your poster at?the Longevity Global Summit Dec. 3-4th, at the?Buck Institute for Research on Aging. ? Do you have a groundbreaking project that's moving forward? This is your chance to showcase your results to a global audience of industry leaders, investors, and fellow visionaries. ? ????Apply to present?here: https://lnkd.in/gKfkGDr9 ???Don’t miss out!?Grab your tickets?while they last: https://lnkd.in/gx8Q8mYT
-
-
CEO & Co-founder, NeuroAge Therapeutics | Founder & Executive Director, Longevity Global
Are you an investor interested in #longevity biotech/healthtech/deep tech looking to meet some amazing founders? Do you want a complimentary VIP ticket to the Longevity Summit Dec 3-4th at the Buck where many of these companies are presenting? DM me for your complimentary ticket and a warm intro to the companies speaking at the Summit. Longevity Summit: https://lnkd.in/gWnVxNQz cc: Ronjon Nag Anastasiya K. (Giarletta) Seifollahi
-
-
Join me at the Buck Institute for Research on Aging this Dec 3-4!
Developing therapeutics for healthy aging requires both new science and business models. #XPRIZEHealthspan Executive Director Jamie Justice, Ph.D. will be speaking at the Longevity Global Summit on Dec. 3. The Summit will deep dive into topics including: ?? Regulatory approval ?? Clocks, biomarkers, and age measurement ?? Data collection …and more! Learn more about the $101M XPRIZE Healthspan global competition and the $10M FSHD Bonus Prize at the event. Register here.?https://lnkd.in/gx8Q8mYT XPRIZE Healthspan is made possible thanks to the generosity of Co-Title Sponsors?Hevolution Foundation?and?SOLVE FSHD, and other individual sponsors.
-
-
CEO & Co-founder, NeuroAge Therapeutics | Founder & Executive Director, Longevity Global
It’s a new dawn for Alzheimer’s therapies. Lots of promising interventions coming in the next 1-3 years.
62k | TMS | Neuroscience | Healthcare | Neuromodulation | Biotech | Business Development at Magstim
?? Amazing Breakthrough in Alzheimer's Treatment ?? A recent phase 2 study revealed that transcranial magnetic stimulation (TMS) can slow cognitive decline in mild to moderate Alzheimer’s patients by 44% compared to a sham treatment. Patients also maintained their ability to perform daily activities, as measured by standardized scales. The therapy targets the precuneus, a critical hub in the brain's default mode network (DMN), which is heavily involved in memory. By using individualized neuromodulation techniques, the treatment reduced behavioral disturbances like anxiety, eating disorders, and sleep disruptions, significantly improving patients' quality of life. This innovative approach uses data-driven targeting to stimulate the most responsive areas of the DMN, showcasing its potential as a safe, accessible treatment option. With a phase 3 trial on the horizon, researchers hope this method will complement existing therapies for Alzheimer’s and provide an alternative for those unable to use antibody-based treatments. Key Points: ?? TMS slowed cognitive decline by 44% in patients with mild to moderate Alzheimer’s. ?? The treatment maintained daily living abilities and improved behavioral symptoms like anxiety and sleep disturbances. ?? The approach uses personalized neuromodulation to target memory-related brain networks, offering a safe, non-invasive alternative to drug therapies. Credit to Fierce Pharma for the great article! Link to original article: https://lnkd.in/gt9NsX4N #TMS #Neuromodulation #Alzheimers
-
-
Could brain fat droplets play a role in Alzheimer's? An NIA-funded study found that microglia in the brain may accumulate fat droplets and secrete chemical messengers that damage neurons. The APOE ?4 genetic risk variant for Alzheimer’s may exacerbate these harmful changes. Learn more about how fat-filled microglia may play a role in the damage caused by Alzheimer’s: https://lnkd.in/dezEwBGh #NIAFunded #NIHAging #Microglia #Alzheimers
-
-
CEO & Co-founder, NeuroAge Therapeutics | Founder & Executive Director, Longevity Global
We are very happy to be holding the 4th Annual Longevity Global Summit again this year at the Buck Institute for Research on Aging. If you haven't been there, the Buck is a non-profit research institute in Novato, CA dedicated to research on healthy aging. Their event space and auditorium are absolutely beautiful and they are doing some of the best science around. Big thanks to the Buck and Eric Verdin for hosting us. You can learn more and purchase Summit tickets here: https://lnkd.in/gWnVxNQz
The Buck Institute for Research on Aging is proud to host the upcoming Longevity Summit 2024! The Summit will feature leaders across biotech, pharma, investment, and research to advance aging interventions and drive innovation in the longevity industry. Don't miss your chance to hear from and interact with top longevity experts! Get your tickets here: https://lnkd.in/gx8Q8mYT Longevity Global #LongevitySummit2024
-
APOE4 allele is the strongest genetic risk factor for Alzheimer's disease. If you are like Chris Hemsworth and have two copies of APOE4, your risk for AD goes up 10-15 fold. Despite this, there are no approved therapies that target APOE directly (and compared to amyloid, a miniscule number of approaches have been tried). One reason is that it's not an easy target to modulate and there is not even consensus on how to modulate it. But we do know that APOE4 is generally associated with increased risk in the Caucasian and Asian populations and less so in African populations. And we also know that APOE2 reduces AD risk. Christin Glorioso, MD PHD and I were recently discussing what would be the best approach to target it and shortly after, Andy Lee informed me of an APOE2 gene therapy approach: https://lnkd.in/eTt63-3X I am in no way associated with Lexeo Therapeutics but I find in fascinating and am curious what my AD friends think of gene therapy with APOE2 (perhaps with simultaneous suppression of APOE4)? Personally, I am a fan of small molecules (in the form of a pill preferably) since you can stop taking them if adverse effects arise but given the lack of those, would you try gene therapy if you had two copies of APOE4?
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference | Lexeo Therapeutics
ir.lexeotx.com